Daily Endocrinology Research Analysis
An IPD meta-analysis across 25 cohorts links isolated hypothyroxinaemia and lower FT4 in pregnancy with higher gestational diabetes risk. A Nature Communications study demonstrates in situ β-cell neogenesis via an ALK3 agonist (THR-123), suggesting a regenerative avenue for diabetes. Real-world data indicate DPP-4 inhibitors reduce dialysis initiation and severe hypoglycemia versus meglitinides in stage 5 CKD with diabetes.
Summary
An IPD meta-analysis across 25 cohorts links isolated hypothyroxinaemia and lower FT4 in pregnancy with higher gestational diabetes risk. A Nature Communications study demonstrates in situ β-cell neogenesis via an ALK3 agonist (THR-123), suggesting a regenerative avenue for diabetes. Real-world data indicate DPP-4 inhibitors reduce dialysis initiation and severe hypoglycemia versus meglitinides in stage 5 CKD with diabetes.
Research Themes
- Thyroid–glucose axis in pregnancy and gestational diabetes risk
- Regenerative strategies for β-cell mass restoration
- Diabetes therapeutics in advanced chronic kidney disease
Selected Articles
1. Association of gestational thyroid function and thyroid autoimmunity with gestational diabetes: a systematic review and individual participant meta-analysis.
Across 25 cohorts (n=63,548), isolated hypothyroxinaemia (low FT4 with normal TSH) was associated with higher gestational diabetes risk versus euthyroidism (adjusted OR 1.52, 95% CI 1.17–1.98). The analysis suggests that lower FT4 levels during pregnancy confer increased GDM risk, whereas subclinical hypothyroidism prevalence was documented but associations are not detailed in the excerpt.
Impact: This IPD meta-analysis refines risk stratification for gestational diabetes by quantifying the contribution of low FT4/isolated hypothyroxinaemia across diverse cohorts.
Clinical Implications: Consider integrating FT4 assessment (not only TSH) into early pregnancy screening to identify women at higher GDM risk and tailor glucose monitoring and prevention strategies.
Key Findings
- Across 25 cohorts (n=63,548), isolated hypothyroxinaemia prevalence was 2.2% and subclinical hypothyroidism 3.2% (in cohorts with TPOAb data).
- Isolated hypothyroxinaemia was associated with increased gestational diabetes risk vs euthyroidism (adjusted OR 1.52, 95% CI 1.17–1.98).
- Lower FT4 during pregnancy was linked to higher GDM risk (as per study interpretation).
Methodological Strengths
- Individual participant data meta-analysis across 25 cohorts with standardized analyses
- Large sample size enabling precise effect estimates and subgroup definitions (e.g., isolated hypothyroxinaemia)
Limitations
- Observational cohort data limit causal inference and residual confounding cannot be excluded
- Heterogeneity across cohorts and incomplete reporting of FT4 thresholds may affect generalizability
Future Directions: Prospective interventional studies assessing whether correcting low FT4/isolated hypothyroxinaemia reduces GDM incidence, and establishing trimester-specific FT4 thresholds.
BACKGROUND: Pregnancy is a state of increased metabolic demand that necessitates major changes in endocrine physiology. Gestational thyroid dysfunction and gestational diabetes are common endocrine conditions of pregnancy that frequently coincide. Although the effects of thyroid hormones on glucose metabolism are well documented, important knowledge gaps remain in terms of the extent and clinical relevance of these effects during pregnancy. The aim of this meta-analysis is to assess the association of thyroid function test results with gestational diabetes and markers of glucose metabolism. METHODS: In this systematic review and individual participant data meta-analysis, we searched Ovid MEDLINE, EMBASE, and Web of Science from database inception to Dec 12, 2024, for prospective population-based cohort studies with individual patient data on thyroid function, gestational diabetes, and measures of glucose homoeostasis during pregnancy.
2. Pancreatic β-cell regeneration in situ by the ALK3 agonist THR-123.
The ALK3 agonist THR-123 induced rapid formation of BrdU-positive islets near ducts and ameliorated hyperglycemia in diabetic mice. Live pancreatic slice imaging and scRNA-seq indicated ductal cells transition through a hybrid ducto-acinar stage to glucose-responsive insulin-expressing cells, supporting predominantly neogenic β-cell formation.
Impact: Provides mechanistic, multi-modal evidence for in situ β-cell neogenesis driven by a drug-like ALK3 agonist, opening a regenerative therapeutic avenue for insulin-dependent diabetes.
Clinical Implications: While preclinical, ALK3 pathway activation could underpin future pharmacological regeneration of β-cell mass; safety, durability, and efficacy in large animals and humans are needed before translation.
Key Findings
- THR-123 reduced hyperglycemia and generated new BrdU-labeled islets, many adjacent to ducts.
- New islets exhibited an intrainsular ductal network distinct from controls.
- Live slice imaging and scRNA-seq showed ductal-to–insulin+ transition via a hybrid ducto-acinar state, indicating neogenesis as the predominant mechanism.
Methodological Strengths
- Convergent evidence from in vivo diabetic mouse models, live organotypic slice imaging, and scRNA-seq
- Use of BrdU lineage labeling and spatial context (duct-adjacent neogenic islets)
Limitations
- Preclinical study; human safety, dosing, and long-term durability are unknown
- Potential off-target BMP pathway effects and fibrosis risks not addressed
Future Directions: Evaluate THR-123 in large-animal diabetes models, define safety/PK, and test combination with immune modulation for type 1 diabetes.
The demonstration that BMP signaling activates progenitor-like populations within pancreatic ducts supports the potential use of BMP receptor agonists to induce islet neogenesis in situ. In this context, we tested the ability of THR-123, a cyclic peptide with BMP-7-like activity, to regenerate β-cell mass in diabetic mice. We show here that treatment with THR-123 reduces hyperglycemia through the rapid formation of new BrdU-labeled islets, many in apposition to ducts. These islets, unlike those from non-diabetic controls, feature an extensive intrainsular network of ductal tissue. The earlier stages of THR-123-induced β-cell formation were reproduced in live pancreatic slices, an organotypic model that allowed us to visualize ductal cells transitioning to glucose-responsive insulin-expressing cells in real time. scRNAseq analyses further suggest that this transition occurs through a hybrid ducto-acinar stage similar to that previously reported in humans. Taken together, our data support the conclusion that these islets arise predominantly by neogenesis. These results pave the way for the design of pharmacological strategies to treat insulin-dependent diabetes.
3. Use of dipeptidyl peptidase-4 inhibitors is associated with lower risk of severe renal outcomes in pre-dialysis patients with Type 2 diabetes.
In 7,271 patients with stage 5 CKD and diabetes (pre-dialysis), DPP-4 inhibitors were associated with a 14% lower risk of a renal composite outcome versus meglitinides (weighted HR 0.86, 95% CI 0.81–0.92), driven by a 17% reduction in renal replacement therapy. Severe hypoglycemia risk was 41% lower with DPP-4 inhibitors.
Impact: Addresses a critical evidence gap in antidiabetic therapy for advanced CKD, using robust comparative effectiveness methods with clinically meaningful endpoints.
Clinical Implications: For stage 5 CKD patients not yet on dialysis, DPP-4 inhibitors may be preferred over meglitinides to minimize dialysis initiation and severe hypoglycemia risk, pending individualized assessment.
Key Findings
- Active-comparator IPTW cohort (Taiwan claims, 2012–2020) included 7,271 pre-dialysis CKD stage 5 patients (5,028 DPP-4i; 2,243 meglitinides).
- DPP-4 inhibitors reduced the renal composite outcome risk by 14% vs meglitinides (weighted HR 0.86, 95% CI 0.81–0.92), primarily via a 17% reduction in renal replacement therapy.
- Severe hypoglycemia risk was 41% lower with DPP-4 inhibitors compared to meglitinides.
Methodological Strengths
- Active-comparator design (meglitinides) with IPTW to address confounding by indication
- Nationwide dataset with hard renal endpoints including dialysis initiation
Limitations
- Observational design with potential residual confounding; laboratory data granularity may be limited
- Drug exposure misclassification and unmeasured socioeconomic/clinical variables possible
Future Directions: Prospective or pragmatic trials comparing DPP-4 inhibitors vs other agents in advanced CKD, and subgroup analyses by dialysis timing and concomitant therapies.
OBJECTIVES: Patients with diabetes and Stage 5 chronic kidney disease (CKD) not on dialysis are susceptible to renal replacement therapy and severe complications. Among limited antidiabetic options in this vulnerable population, dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4i) are widely used; however, supporting evidence is scant. This study assessed severe renal outcomes associated with DPP-4i in diabetic and pre-dialysis patients. METHODS: This study employed an active-comparator and propensity score-based inverse probability of treatment weighting approach, using Taiwan's nationwide healthcare claims database from 2012 to 2020. We identified patients with diabetes and CKD stage 5 not on dialysis who received erythropoietin (erythropoietin-stimulating agent), a drug reimbursed for patients with an estimated glomerular filtration rate <15 mL/min/1.73 m